Abstract Number: 2525 • ACR Convergence 2025
Point-of-Care Risk Factors for Systemic Disease in Patients Presenting with Small Vessel Vasculitis of the Skin
Background/Purpose: Small vessel vasculitis (SVV) presenting in the skin may be skin-limited or a manifestation of systemic vasculitis or an underlying autoimmune disease. However, no…Abstract Number: 2260 • ACR Convergence 2025
Generative AI model identifies patients with Rheumatoid Arthritis (RA) months prior the diagnosis date: results from a large real-world RA cohort
Background/Purpose: Clinical notes typically contain a valuable trove of information which is rarely used in predictive modeling given the complexity of working with unstructured data.…Abstract Number: 1988 • ACR Convergence 2025
Advancing Vascular Assessment: Combining NIRS-VOT and Ultrasound-Based Brachial Artery Diameter for Improved Diagnostics in Healthy Controls and APS
Background/Purpose: Near-Infrared Spectroscopy combined with Vascular Occlusion Test (NIRS-VOT) is a non-invasive diagnostic method for assessing microvascular function. However, its diagnostic accuracy is often limited…Abstract Number: 1186 • ACR Convergence 2025
Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry
Background/Purpose: Recurrent pericarditis (RP) is a chronic autoinflammatory disease mediated by IL-1 that requires long-term treatment. While the 2015 European Society of Cardiology Guidelines position…Abstract Number: 1052 • ACR Convergence 2025
“Prednisone… A Necessary Evil…” Developing an Evidence-Based Benefits vs. Harms Shared Decision-Making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Background/Purpose: Guidelines recommend limiting chronic prednisone use ( >5 mg/d for >3-6 mos.) given higher risks of fractures, infections, and damage. Yet, patients struggle to…Abstract Number: 1051 • ACR Convergence 2025
Mitigating Hydroxychloroquine (HCQ) Nonadherence by Clarifying Misbeliefs Using a Shared Decision-Making Tool (HCQ-SAFE©) Across Two Different Rheumatology Centers
Background/Purpose: Hydroxychloroquine (HCQ) prolongs disease-free and damage-free survival in lupus (SLE). Yet, ~80% of patients stop taking HCQ resulting in poor outcomes including early mortality.…Abstract Number: 1050 • ACR Convergence 2025
Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Background/Purpose: Hydroxychloroquine (HCQ) is a key therapy for lupus (or SLE). Yet, challenged to weigh benefits vs. harms, ~80% of patients self-discontinue HCQ. Shared decision-making…Abstract Number: 0449 • ACR Convergence 2025
Consistency of CDAI Low-Disease Activity (LDA) Outcomes with Time in a Large US Registry: Association With Patient-Reported Clinical Outcomes and Measures of Quality of Life
Background/Purpose: Low disease activity has been identified as a treatment goal for the treatment of RA. A singlecenter RA registry (BRASS) reported a difference in…Abstract Number: 1315 • ACR Convergence 2024
From Presentation to Publication: Tracking the Publication Rate of Abstracts Presented at American College of Rheumatology Convergence Conference in the Years 2015 and 2018
Background/Purpose: The ACR Convergence meeting attracts rheumatology researchers worldwide to present their peer- reviewed abstracts for a global audience either as a poster or oral…Abstract Number: 1358 • ACR Convergence 2024
A Step Towards Personalised Medicine – Development and Efficacy of Machine Learning Based Smart-Web Application for Prediction of Steroid Induced Hyperglycemia in Patients with Rheumatoid Arthritis and Other Autoimmune Rheumatic Diseases
Background/Purpose: Steroids play a key role in treating rheumatic diseases due to their anti-inflammatory effects. However, long-term or high-dose use leads to side effects like…Abstract Number: 2395 • ACR Convergence 2024
Validation Cohort of a Tool to Predict Proliferative Histological Class in Lupus Nephritis Based on Clinical and Laboratory Data – LUCAS Study (Lupus Nephritis Class Assessment System)
Background/Purpose: Lupus nephritis (LN) is an important cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE), and kidney biopsy is the gold…Abstract Number: 2605 • ACR Convergence 2024
Clarifying Misbeliefs & Resolving Decisional Conflicts About Hydroxychloroquine (HCQ) Through a Shared Decision-Making Tool (HCQ-SAFE©)
Background/Purpose: Treatment of lupus (or SLE) is complex, especially for young patients who are committed to take hydroxychloroquine (HCQ) lifelong, which carries some risk, albeit…Abstract Number: 0375 • ACR Convergence 2024
Patient Outcomes During the Implementation of a Patient Decision-Aid for a Diverse Population of Systemic Lupus Erythematosus: A Study in 15 U.S. Rheumatology Clinics
Background/Purpose: To implement a self-administered patient decision-aid (PtDA) for lupus in outpatient clinics, assess its reach/penetration within each clinic, and examine patient outcomesMethods: An effective…Abstract Number: 1237 • ACR Convergence 2024
The Art of Choosing Together: Unveiling the Patient’s Perspective in Rheumatology
Background/Purpose: Scientific evidence supports that shared decision-making (SDM) can improve adherence to treatment, patient satisfaction, quality of life, clinical outcomes, and healthcare costs. However, challenges…Abstract Number: 1306 • ACR Convergence 2024
A Comparative Analysis of ChatGPT-4, Microsoft’s Bing and Google’s Bard at Answering Rheumatology Clinical Questions
Background/Purpose: The role of artificial intelligence (AI) is rapidly expanding in medical fields, with an increased frequency of use by both patients and providers. There…
- 1
- 2
- 3
- …
- 5
- Next Page »